價(jià)格 | 詢價(jià) |
包裝 | 10mM |
最小起訂量 | 10mM |
發(fā)貨地 | 上海 |
更新日期 | 2024-11-05 |
中文名稱:LY303511 (mTOR抑制劑) | 英文名稱:LY303511 (mTOR抑制劑) |
有效期: 一年 | 產(chǎn)品類別: MAPK與PI3K/Akt通路 mTOR Signaling |
產(chǎn)品編號(hào) | 產(chǎn)品名稱 | 產(chǎn)品包裝 | 產(chǎn)品價(jià)格 |
SF2816-10mM | LY303511 (mTOR抑制劑) | 10mM | 114.00元 |
化學(xué)信息:
化學(xué)名 | 8-phenyl-2-piperazin-1-ylchromen-4-one | |
簡(jiǎn)稱 | LY303511 | |
別名 |
LY-303511, LY303511 |
|
中文名 | N/A | |
化學(xué)式 | C19H18N2O2 | |
分子量 | 306.36 | |
CAS號(hào) | 154447-38-8 | |
純度 | 98% | |
溶劑/溶解度 |
Water<1mg/ml; DMSO30.6mg/ml; Ethanol<1mg/ml |
|
溶液配制 | 5mg加入1.63ml DMSO,或者每3.06mg加入1ml DMSO,配制成10mM溶液。SF2816-10mM用DMSO配制。 |
生物信息:
產(chǎn)品描述 | LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. | ||||
信號(hào)通路 | PI3K/Akt/mTOR | ||||
靶點(diǎn) | - | - | - | - | - |
IC50 | - | - | - | - | - |
體外研究 | 100μM LY303511 significantly reduced the fraction of cells in S phase. The proportion of cells in G2/M remained unchanged, indicating that cells were arrested in both G1 and G2/M. In contrast, rapamycin increased the G1 population by reducing the proportion of cells in both S and G2/M. The effects of 10μM LY303511 and rapamycin on the reduction in S phase cells were additive to that of 10μM LY303511 alone (P=0.056). In MIN6 insulinoma cells, wortmannin (100nM) had no effect on whole-cell outward K+ currents, but LY294002 and LY303511 reversibly blocked currents in a dose-dependent manner (IC50=9.0+/-0.7mM and 64.6+/-9.1mM, respectively). Western blotting confirmed the specific inhibitory effects of LY294002 and wortmannin on insulin-stimulated PI3K activity. Both LY294002 and LY303511 increased the activity of protein kinase A (PKA). Moreover, PKA blockade by the small molecule inhibitor H89 decreased the LY294002/LY303511-mediated increase in GJIC. | ||||
體內(nèi)研究 | PND4 ovaries were cultured for 8 days in control medium or medium containing VCD (30μM) in the presence or absence of LY303511 (20μM). Incubation with LY303511 alone caused a reduction (P<0.05) in primordial and small primary follicle numbers. On the other hand, whereas VCD alone depleted (P<0.05) primordial and small primary follicle numbers, this depletion was not prevented by co-incubation with LY303511. | ||||
臨床實(shí)驗(yàn) | N/A | ||||
特征 | N/A |
相關(guān)實(shí)驗(yàn)數(shù)據(jù)(此數(shù)據(jù)來(lái)自于公開(kāi)文獻(xiàn),碧云天并不保證其有效性):
酶活性檢測(cè)實(shí)驗(yàn) | |
方法 | N/A |
細(xì)胞實(shí)驗(yàn) | |
細(xì)胞系 | N/A |
濃度 | N/A |
處理時(shí)間 | N/A |
方法 | N/A |
動(dòng)物實(shí)驗(yàn) | |
動(dòng)物模型 | N/A |
配制 | N/A |
劑量 | N/A |
給藥方式 | N/A |
產(chǎn)品編號(hào) | 產(chǎn)品名稱 | 包裝 |
SF2816-10mM | LY303511 (mTOR抑制劑) | 10mM×0.2ml |
SF2816-5mg | LY303511 (mTOR抑制劑) | 5mg |
SF2816-25mg | LY303511 (mTOR抑制劑) | 25mg |
— | 說(shuō)明書(shū) | 1份 |
保存條件:
????????-20℃保存,至少一年有效。5mg和25mg包裝也可室溫保存,至少6個(gè)月有效。如果溶于非DMSO溶劑,建議分裝后-80℃保存,預(yù)計(jì)6個(gè)月內(nèi)有效。
成立日期 | 2007-07-19 (18年) | 注冊(cè)資本 | 1000.000000萬(wàn)人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 500萬(wàn)-1000萬(wàn) |
主營(yíng)行業(yè) | 生化試劑,核苷,核苷酸,寡核苷酸,抗體,蛋白組學(xué),生物活性小分子 | 經(jīng)營(yíng)模式 | 試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP1年
|
長(zhǎng)沙市滿碩商行
|
2024-11-16 | |
詢價(jià) |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-11-15 | |
¥1280 |
VIP1年
|
湖北艾普蒂生物工程有限公司
|
2024-11-15 |